Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2001): Laack E+, Ann Oncol 12(12), 1761 (with gemcitabine)
(1998): Hoff PM+, Cancer 82, 965
Pigmentation
(1994): Cecchi R+, Dermatology 188, 244
Pruritus
Rash (sic) (10%)
(2005): Serin D+, Br J Cancer 92(11), 1989 (with epirubicin)
(2002): Bonneterre J+, Br J Cancer 87(11), 1210 (40%) (with
fluorouracil)
(1989): Marty M+, Nouv Rev Fr Hematol (French) 31, 77 (12%)
Hair
Hair – alopecia (12%)
(2004): Martin M+, Clin Breast Cancer 5(5), 353 (53%) (with
doxorubicin)
(1994): Gasparini G+, J Clin Oncol 12, 2094
(1989): Marty M+, Nouv Rev Fr Hematol (French) 31, 77
Other
Anaphylactoid reactions/Anaphylaxis
Cough
(2005): Lena MD+, Lung Cancer 48(1), 129 (with cisplatin)
Death
(2005): Winton T+, NEnglJMed352(25), 2589 (%) (with
cisplatin)
Extravasation
(2001): Bertelli G+, Tumori 87(2), 112
Inappropriate secretion of antidiuretic hormone (SIADH)
(1998): Garrett CA+, Ann Pharmacother 32(12), 1306
Infections
(2002): Bonneterre J+, Br J Cancer 87(11), 1210 (with
fluorouracil)
Injection-site irritation (1–10%)
Injection-site necrosis (1–10%)
Injection-site pain
(2001): Long TD+, Am J Clin Oncol 24(4), 414
Injection-site phlebitis (12%)
(1998): Sauter C+, Schweiz Med Wochenschr (German) 128, 343
(1989): Marty M+, Nouv Rev Fr Hematol (French) 31, 77 (12%)
Myalgia/Myositis/Myopathy/Myotoxicity (